ALEXANDRIA, Va., April 7 -- United States Patent no. 12,595,302, issued on April 7, was assigned to SANYOU BIOPHARMACEUTICALS Co. LTD. (Shanghai).
"CLDN18.2 binding molecule" was invented by Yongcong Tan (Shanghai), Guojun Lang (Shanghai), Chao Kong (Shanghai), Chanjuan Liu (Shanghai), Min Deng (Shanghai), Qi Wu (Shanghai), Jing Zhang (Shanghai), Wenhai Zhang (Shanghai) and Baoguo Fan (Shanghai).
According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is a novel CLDN18.2 binding molecule. Also disclosed are a nucleic acid molecule encoding the CLDN18.2 binding molecule, an expression vector and a host cell for expressing the CLDN18.2 binding molecule. Further disclosed are a method for producing the CLDN18.2 ...